Highlights: What Pharmacists Need to Know about ACIP’s Latest 2023 Vaccination Schedule Updates
Drug Topics
JANUARY 3, 2023
Keep your pharmacy services up to date with the latest 2023 ACIP vaccination schedule updates and recommendations.
Drug Topics
JANUARY 3, 2023
Keep your pharmacy services up to date with the latest 2023 ACIP vaccination schedule updates and recommendations.
Pharmacy Times
JANUARY 3, 2023
In addition to the physical symptoms of long COVID, patients have reported vocal, verbal, and cognitive issues that disrupt their ability to communicate.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
JANUARY 3, 2023
The CDC has reported an increase in drug overdose deaths from 2019 to 2022 in adolescents aged 10 to 19 years.
STAT
JANUARY 3, 2023
A diverse and inclusive workforce benefits science and research. But unless it includes people living with a disability — the largest minority group in the U.S. and around the world — research will never be fully representative and science will not reach its full potential. Although 27% of U.S. adults live with a disability, only 10% of science, engineering, and health doctorate holders, and less than 2% of researchers funded by the National Institutes of Health, report having a di
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharmacy Times
JANUARY 3, 2023
Study finds a strong decline in hepatitis C incidence in the years immediately following broad access to direct-acting antiviral drugs.
Drug Topics
JANUARY 3, 2023
Researcher modeling the cost effectiveness of chimeric antigen receptor T-cell therapy (CAR-T) therapy and antibody conjugate found that they fell short.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
PharmaVoice
JANUARY 3, 2023
Durect’s chief medical officer altered his retirement plans to take a leading role at the company, which is developing a treatment for severe alcohol-associated hepatitis.
Fierce Pharma
JANUARY 3, 2023
COVID-19 tracker: AstraZeneca workers who were fired for refusing vaccine file lawsuit. kdunleavy. Tue, 01/03/2023 - 10:31.
pharmaphorum
JANUARY 3, 2023
Encouraged by new data, Newron Pharmaceuticals has said it will start a registration study of would-be blockbuster evenamide in treatment-resistant schizophrenia (TRS) later this year. The Italian biopharma said it had decided to press ahead with the new study after assessing results from 100 patients with TRS in open-label studies who received the glutamate modulator drug as an add-on to their current therapy for more than six months.
Pharmacy Times
JANUARY 3, 2023
Pharmacists play a vital role in counseling and educating families about medication safety for these products.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
pharmaphorum
JANUARY 3, 2023
Research advises against aggressive cancer treatment at the end-of-life stages of the disease. At the same time, the pharmaceutical industry is creating a greater number of oncology treatments that could provide breakthroughs for patients where none previously existed. Ben Hargreaves examines why there is no easy answer to the question of when palliative care is the right option for patients.
STAT
JANUARY 3, 2023
The number of people in the United States hospitalized with Covid-19 is about to surpass the figure reached during this summer’s spike, federal data show , as a confluence of factors — from the continued evolution of the coronavirus to holiday gatherings — drives transmission. Notably, the number of people hospitalized with Covid — roughly 40,000 — is still far below the winter waves of 2020-2021 and 2021-2022 (the wave driven by the original Omicron variant) a
Drug Store News
JANUARY 3, 2023
Gail Lebovic’s recent move in health care came in 2020, with the formation of Silicon Valley Innovations, and its OTC flagship product, NasoClenz.
STAT
JANUARY 3, 2023
If rebates had been required for price hikes on most of the nearly 100 medicines covered by Medicare during a recent three-year period, the U.S. government program would have saved $3.7 billion, or 3% of the total spending on so-called Part B medicines, a new analysis found. More specifically, 70 of the 93 top-selling drugs covered by the Medicare Part B program – which are typically pricier medicines that are administered by physicians or in hospitals – between 2018 and 2020 would
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
The Checkup by Singlecare
JANUARY 3, 2023
After engaging in a fun holiday season with indulgent food and festive drinks, it’s not unusual to long for a reset. For some this takes the form of “Dry January,” a month without drinking any alcohol—or significantly reduced alcohol consumption. “Starting a new year is a good time to make commitments for healthier behaviors,” says Anna Legreid Dopp, Pharm.D. , a senior director at American Society of Health-System Pharmacists (ASHP).
STAT
JANUARY 3, 2023
As inflation-weary shoppers try to make ends meet, many are turning to a modern twist on the layaway plan: buy now, pay later. But while platforms like Afterpay and Affirm were originally built to take the sting out of online shopping, these new financing options are beginning to creep into the world of health care. “Buy now, pay later is a small fraction of the health space, but it is exploding,” said Jay Zagorksy, an economist at the Questrom School of Business at Boston Universi
The Checkup by Singlecare
JANUARY 3, 2023
What causes diabetes? Diagnosis, prevention, and treatment. Diabetes, also known as diabetes mellitus, is one of the most common health conditions, with around one million Americans diagnosed with diabetes each year. Diabetes can develop in virtually anyone, although, according to the American Diabetes Association (ADA), it is more prevalent in African Americans, Asian Americans, and Hispanics. .
STAT
JANUARY 3, 2023
Over the past three years, many Americans learned more about epidemiology than they ever knew before. From Covid-19 to mpox to polio, a new generation of citizen scientists is now joining trained professionals in analyzing public health data, forecasting trends, and making personal decisions based on the latest outbreak patterns. But professionals and everyday observers alike are running up against one of the most significant problems in the world of health care data science: the available infor
Pharmacy Times
JANUARY 3, 2023
Indication can play a major role in pharmacists recommending brain health products.
STAT
JANUARY 3, 2023
A House investigation released last week unearthed a trove of documents that shed new light on the polarizing approval and disastrous rollout of Aduhelm, the first new drug for Alzheimer’s disease in two decades. But crucial questions remain for the Food and Drug Administration, Biogen, and the future of treating Alzheimer’s disease. The FDA has not made clear just what it has changed since the Aduhelm debacle, and the revelations about its inner workings — and the blow to i
Fierce Healthcare
JANUARY 3, 2023
Oregon health agency approves Amazon, One Medical acquisition, moving $3.9B deal one step forward. hlandi. Tue, 01/03/2023 - 21:44.
STAT
JANUARY 3, 2023
Paying people to participate in medical research has been proposed as a way to narrow racial and ethnic gaps in who signs up for clinical trials and other research studies. But a new study finds that if the amount is too small, it could have the opposite effect. Offering $100 to participate in a Covid-19 study enticed affluent and white people while doing little to increase the participation of people from low-income or non-white households.
Fierce Healthcare
JANUARY 3, 2023
Scripps Health reaches $3.5M proposed settlement to compensate victims of 2021 ransomware attack. aburky. Tue, 01/03/2023 - 13:13.
STAT
JANUARY 3, 2023
For almost three years, hospitals and health insurers have been riding the waves of the Covid-19 pandemic. Even though they can better predict what lies ahead in 2023, there remain several big unknowns. STAT’s business reporters will be paying attention to three trends in particular: the end of the public health emergency, how hospital price hikes will affect people’s paychecks, and Medicare Advantage’s explosive growth.
Pharmacy Times
JANUARY 3, 2023
Patient-centric models of medication delivery that provide cost, transparency, convenience, and accessibility solutions are vital for patients to successfully navigate the current health care system.
STAT
JANUARY 3, 2023
BEIJING — The Chinese government sharply criticized COVID-19 testing requirements imposed on passengers from China and threatened countermeasures against countries involved, which include the U.S. and several European nations. “We believe that the entry restrictions adopted by some countries targeting China lack scientific basis, and some excessive practices are even more unacceptable,” Foreign Ministry spokesperson Mao Ning said at a daily briefing Tuesday.
Drug Store News
JANUARY 3, 2023
Albertsons has been granted a Jan. 17 review of the temporary restraining order against its previously announced $6.85-per-common-share special dividend.
STAT
JANUARY 3, 2023
Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter: Last year, a novel combination pill developed by Karuna Therapeutics reduced psychosis and related symptoms experienced by patients with schizophrenia, achieving the main goals of a late-stage clinical trial. This quarter, the company hopes to follow up those positive results with the readout of a second, Phase 3 study.
Drug Store News
JANUARY 3, 2023
The United States Court of Appeals for the Federal Circuit has granted a motion to temporarily enjoin the generic launch by Teva and Apotex of Hetlioz.
Fierce Pharma
JANUARY 3, 2023
Lilly, Merck double down on peptide-targeted drug delivery, betting billions in biobucks on PeptiDream pacts. ntaylor. Tue, 01/03/2023 - 08:31.
Fierce Healthcare
JANUARY 3, 2023
'Podnosis': Digital redlining in healthcare and breaking down barriers to care for gender-diverse populations. tcarey. Tue, 01/03/2023 - 15:06.
Fierce Pharma
JANUARY 3, 2023
Unicycive's pivotal trial of rival to Takeda kidney drug hits main goal, clearing path to FDA filing. ntaylor. Tue, 01/03/2023 - 03:20.
Fierce Healthcare
JANUARY 3, 2023
Physician group practices struggle with bundled payments: study. fdiamond. Tue, 01/03/2023 - 14:29.
European Pharmaceutical Review
JANUARY 3, 2023
A marketing authorisation application (MAA) has been submitted by The Janssen Pharmaceutical Companies of Johnson & Johnson to the European Medicines Agency (EMA) for approval of talquetamab, a bispecific t-cell engager antibody for the treatment of patients with relapsed or refractory multiple myeloma (RRMM). Talquetamab is an investigational, off-the-shelf treatment targeting both GPRC5D, a novel drug target that is on some normal cells but overexpressed on myeloma cells, and CD3 on t-cell
Let's personalize your content